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Mechanisms of dexamethasone-mediated inhibition of cAMP- eling. In the kidney, mainly the tissue-type plasminogen
induced tPA expression in rat mesangial cells. activator (tPA) is implicated in the course of many exper-
Background. Glucocorticoids are efficiently used as anti- imental nephropathies and other pathological condi-inflammatory and immunosuppressive therapies of renal dis-
tions. Besides the fibrinolytic activity, the tPA system ineases. However, long-term treatment often is associated with
net changes in the turnover of extracellular matrix (ECM) concert with its endogenous inhibitors, plasminogen acti-
components. vator inhibitors (PAIs) are key participants in main-
Methods. We examined the impact of glucocorticoids on taining the balance of proteolytic-antiproteolytic activ-cAMP-triggered expression of tissue plasminogen activator
ity, which determines the turnover of extracellular matrix(tPA), a protease prominently involved in glomerular ECM
turnover. (ECM) [1, 2]. A role for plasmin in the activation of
Results. By ELISA, the db-cAMP-mediated increase in ex- several pro-matrix metalloproteinases (MMPs) is of par-
tracellular tPA activity secreted by mesangial cells (MC) was
ticular interest, since plasminogen activators (PAs) aremarkedly reduced in the presence of 100 nmol/L dexametha-
produced by a variety of different cell types involved insone. The decrease of enzymatic activity was accompanied by
an attenuation of tPA expression, as shown by Northern blot the inflammatory response, most prominently by macro-
analysis. Furthermore, dexamethasone increased the steady- phages [3]. Dysregulation of the PA system resulting
state mRNA level of the tPA-inhibitor 1 (PAI-1), thereby
in a decrease in glomerular fibrinolytic activity due toproviding an additional mode of regulation of tPA activity.
decreased tPA activity has been demonstrated in severalMutational analysis revealed that the inhibition of tPA expres-
sion was localized within the proximal 2.3 kb of the 5-flanking forms of glomerulonephritis and end-stage renal disease
region of the rat tPA gene and critically depended on a cAMP (ESRD) in humans [4, 5]. A decrease in the systemic fi-response element (CRE) at position 185. EMSA demon-
brinolytic activity has been associated with an increasedstrated that binding to this CRE was affected by dexametha-
risk of glomerular fibrin deposition in hemodialysis pa-sone, since the db-cAMP–caused DNA binding of CREB and
C/EBP-immunopositive complexes was substantially reduced tients [6]. Furthermore, a deficiency in tPA leads to severe
by dexamethasone. In parallel, dexamethasone decreased the functional and histological exacerbation of glomerularnuclear abundance of db-cAMP–induced C/EBP and phos-
damage in a mouse model of proliferative glomerulone-phorylated CREB protein without affecting the total level of
either transcription factor. phritis when compared to wild-type mice [7]. These latter
Conclusions. Suppression of cAMP-stimulated tPA expres- observations suggest that tPA may protect against renal
sion by glucocorticoids occurs by interference with CREB and injury in crescent glomerulonephritis [7].C/EBP, the major transcription factors mediating cAMP re-
We have previously reported that rat mesangial cellssponses. These observations may provide the molecular basis
for the sclerotic processes within the glomerulus often compli- (MC) can express a variety of matrix metabolizing enzymes,
cating chronic glucocorticoid treatment. most abundantly matrix metalloproteases-2 (MMP-2)
and -9 (MMP-9; also denoted as gelatinases A and B,
respectively), and the serine protease tPA [8, 9]. In MC,The plasminogen/plasmin system provides the basis
expression of these enzymes is highly induced by pro-for proteolytic activity in a number of biological pro-
inflammatory stimuli, including interleukin-1 (IL-1)cesses characterized by cell migration and tissue remod-
and tumor necrosis factor- (TNF-) [8, 10, 11].
In contrast to MMPs, tPA gene expression is not only
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induced by pro-inflammatory cytokines, but also by cy-activator, transcription factors, immunosuppression, glomerulosclero-
sis, crescent glomerulonephritis. clic adenosine 3,5-monophosphate (cAMP)-elevating
agents such as forskolin [12, 13]. Physiologically hor-Received for publication November 29, 2001
mones coupling in a stimulatory fashion to adenylateand in revised form April 23, 2002
Accepted for publication April 24, 2002 cyclase up-regulate tPA expression, as it has been re-
ported for follicle stimulating hormone (FSH) [14]. The 2002 by the International Society of Nephrology
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cAMP-responsiveness of tPA expression most probably All supplements were purchased from Gibco BRL, Life
relies on the existence of a highly conserved, species- Technologies (Eggenstein, Germany). The N2, 2-O-Dibu-
specific CRE within the rat tPA gene promoter [15], since tyrylguanosine 3:5-cyclic monophosphate used in this
deviations from this sequence strongly reduce the effi- study was from Sigma-Aldrich (Deisenhofen, Germany).
ciency of the cAMP response in human cells [14]. How- Determination of cell numbers was done by use of a Neu-
ever, in human MC activation of the protein kinase A bauer chamber. For RNA experiments and preparation
pathway causes a superinduction of the phorbol 12-myri- of nuclear extracts 3.0 to 5.0  106 of MC/10-cm culture
state 13-acetate (PMA)-induced tPA mRNA level, thus dish were used between passages 8 and 19. For determi-
demonstrating that a stimulatory influence of cAMP on nation of the tPA activity of cellular supernatants 1.0 to
tPA expression is also in certain human cells [16]. 1.5  106 MC were grown on six-well plates and experi-
Besides cAMP-mediated signals, glucocorticoids (GCs) ments performed in triplicate.
have been shown to be potent regulators of tPA gene
Measurements of tPA activity in MC supernatantsexpression [12]. Since GCs are still among the most po-
by ELISAtent anti-inflammatory and immunosuppressive drugs
currently available for the treatment of many inflamma- Quantitative determination of tPA activity in the cel-
tory kidney diseases, we tested for possible modulatory lular supernatants was done using the Chromolize tPA-
effects of GCs on the cAMP-triggered tPA expression ELISA from Biopool (Umea, Sweden). In this enzyme-
in rat glomerular mesangial cells. The mechanisms of linked immunosorbent assay (ELISA) the sample tPA
glucocorticoid receptor (GR)-dependent modulation of was captured by a monoclonal anti-tPA antibody on the
gene transcription involves different modes of action, microtest wells without inhibiting tPA activity. After
including a direct interaction with DNA motifs deline- several wash steps with a mild detergent the tPA sub-
ated as glucocorticoid response elements (GREs), which strate consisting of plasminogen, a plasmin-sensitive
most commonly result in an enhanced transcriptional chromogenic substrate and tPA activity promoters were
activity of the corresponding target genes. In contrast, added and incubated for 90 minutes. The absorbance
most of the suppressive effects on gene expression can at 405 nm with a reference wavelength at 495 nm was
be attributed to a mutual interaction between the GR and measured and tPA activity was determined by a calibra-
transcriptional activators, including activator protein-1 tion curve using human single-chain tPA as a standard.
(AP-1) [17], nuclear factor-B (NF-B) [18, 19], signal Routinely, 100 L of the supernatants were directly
transducer and activator of transcription-5 (STAT-5) subjected to the microtest strip wells of the ELISA.
[20], CCAAT/enhancer binding protein (C/EBP) [20]
and cAMP responsive element binding protein (CREB) Determination of tPA antigen in conditioned media
[21]. The present study demonstrates that long-term treat-
Levels of tPA antigen in cell culture supernatants werement of MC with dexamethasone strongly suppresses di-
determined by the Tint Elize tPA ELISA from Biopool.butyrylguanosine (db)-cAMP-mediated expression of
Confluent MC (1.0 to 1.5  106 cells) on six-well platestPA mainly by interfering with the activation and DNA-
were incubated in DMEM without FCS and stimulatedbinding of CREB and C/EBP transcription factors.
with or without agents for the indicated time periods.
Twenty microliters of conditioned media were directly
METHODS transferred to the microtest strip wells of the ELISA
plate. All further procedures were performed followingChemicals
the manufacturer’s instructions. The absorbance at 492Dexamethasone was purchased from Calbiochem No-
nm was measured in a microtest plate spectrophotometervabiochem (Bad Soden, Germany). All other chemicals
and tPA levels were determined with a calibration curvewere purchased from Sigma (Deisenhofen, Germany).
using human tPA as a standard.
Cell culture
cDNA clones and plasmidsPrimary glomerular MC from Sprague-Dawley rats
A cDNA insert of 0.72 kb of the rat tPA gene waswere isolated as described previously [22]. The cells were
generated by reverse transcription from mRNA of MCgrown in RPMI 1640 supplemented with 10% heat-inac-
stimulated with IL-1 using internal primers from thetivated fetal calf serum (FCS), 2 mmol/L glutamine, 5
complete sequence of rat mRNA (deposited in the Gen-ng/mL insulin, penicillin (100 U/mL), and 100g/mL strep-
bank/EMBL Databases under accession No. M 23697).tomycin. Serum-free pre-incubations were performed in
The following primers were used: 5-AGC AAA ATGDulbecco’s modified Eagle’s medium (DMEM) supple-
AAG GGA GAG CTG-3 (sense) and 5-ATC ATGmented with 0.1 mg/mL of fatty acid-free bovine serum
GAA TTC CAT GGG AGG (antisense). The bluntalbumin (BSA) for 24 hours before treatment with the
ended polymerase chain reaction (PCR) fragment wasdifferent agents. Dexamethasone was given in pre-incu-
bations of 30 minutes before addition of other agents. cloned into the EcoRV cloning site of pBluescript-II KS
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Table 1. Gene-specific binding site sequences for(Stratagene GmbH, Heidelberg, Germany) to generate
wild-type and mutant oligonucleotides
“pKS-tPA-rat.” A cDNA insert of 0.9 kb of the rat PAI-1
5-ATGGCAATCCTTTGACTAAAATCAAAGT-3gene was generated using internal primers from the com-
996 AP-1 969plete sequence of the rat PAI-1 mRNA (accession No.
3-TACCGTTAGGAAACTGATTTTAGTTTCA-5M 24067) and cloned into EcoRV/Hind III-cut pBlue-
script-II KS to generate “pKS-PAI-1-rat.” The follow-
5-ATGGCAATCCTTTGACTTGAATCAAAGT-3ing primers were used: 5-TGA TCG CCC GAT ATC






Total cellular RNA was extracted from MC using the 3-ACACTAAGCTACTGCAGTCATGCCACTTAT-5
Trizol reagent (Gibco BRL, Life Technologies). After
5-TGTGATTCGATGGTGTCAGTACGGTGAATA-3UV cross-linking, 20 g of total RNA were successively
195 CRE mut 166hybridized to 32P-labeled SacI/KpnI digested cDNA
3-ACACTAAGCTACCACAGTCATGCCACTTAT-5clones described in the last section, thereby liberating
inserts of corresponding fragment sizes. cDNA probes
(2  10 6 cpm/mL) were radioactively labeled with
32PdCTP (Amersham Buchler GmbH and CoKG, Braun-
of a double point mutation into the AP-1 site (TGACschweig, Germany) by random priming. To correct for
TAA to TGACTTG) to generate pGL-tPA 	AP-1 wasvariations in RNA amounts blots were finally rehybrid-
done using the following (forward) primer: 5-ATGGCAized with a 32P-labeled SacI/KpnI insert from a human
ATCCTTTGACTTGAATCAAAGT-3 (correspondingGAPDH cDNA clone (accession No. NM 017008) or
to a region from 996 to 969). Generation of a doublewith a 32P-labeled cDNA insert from mouse 18S ribo-
transition within the CRE binding site (TGACGTCAsomal RNA (Ambion, Austin, TX, USA). Membranes
to TGGTGTCA) to generate pGL-tPA 	CRE was doneused for RNA transfers were obtained from NEN Life
using the following (forward) primer: 5-TGTGATTCScience Products (Boston, MA, USA). Specific signals
GATGGTGTCAGTACGGTGAATA-3.were quantified densitometrically using an automated
All mutant constructs were generated using the Quikdetector system BAS 1500 from Fuji film (Raytest,
Change Site-Directed Mutagenesis Kit (Stratagene, Hei-Straubenhardt, Germany).
delberg, Germany). Transient transfections of MC were
Western blot analysis performed using the Effectene reagent (Quiagen, Hil-
den, Germany). Transfections were performed followingNuclear cell extracts (20 to 30 g) were used for detec-
the manufacturer’s instructions. The transfections weretion of nuclear level of C/EBP, CREB, phospho-CREB
done as triplicates and repeated at least three times toand glucocorticoid receptor (GR), respectively. Total
ensure reproducibility of the results. Transfection withcellular levels were analyzed using 50 g of total cellular
pRL-CMV coding for Renilla luciferase was used for con-extracts as described previously [23]. Blots were succes-
trol of transfection efficiency. Luciferase activities weresively probed with anti-CREB, anti-C/EBP and anti-
measured with the dual reporter gene system (Promega,C/EBP
 antibodies, respectively, without prior stripping.
Charbonnie`res, France) using an automated chemilumi-An antibody raised against phosphorylated CREB was
nescence detector (Berthold, Bad Wildbad, Germany)purchased from New England Biolabs (Frankfurt am
Main, Germany). All other antibodies were obtained
Electrophoretic mobility shift assayfrom Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Preparation of crude nuclear extracts from cultured
Cloning of rat tPA promoter and transient transfections MC and subsequent electrophoretic mobility shift assay
(EMSA) was done as described previously [24]. Consen-A 2.3 kb promoter fragment from the rat tPA gene was
sus oligonucleotides for CRE were obtained from Santacloned by PCR using the gene specific primers [15] (acces-
Cruz Biotechnology.sion. No. S-73569) as follows: “tPA-prom. sense”: 5-AG
Competition experiments were done by co-incubationCCT GAGTTACATCGTCAGTTCCAA-3 “tPA-prom.
with a 10- to 100-fold excess (10 to 100 pmol) of unla-anti-sense”: 5-GCTTCTCCTTG GCGCTGAGCTGA
beled double-stranded oligonucleotide in the DNA-pro-TTA-3, and subsequently was subcloned into Eco RV
tein binding reaction. The sequences for wild-type andcut pGL-III Basic vector via blunt end ligation. The
mutant oligonucleotides coding for gene specific bindingorientation of insertion and sequence was confirmed us-
sites are summarized in Table 1. Polyclonal antibodiesing an automated sequence analyzer ABI 310 (PE Ap-
plied Biosystems, Weiterstadt, Germany). Introduction used for supershift experiments were purchased from
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Santa Cruz Biotechnology. For supershift analysis 2 L
of the antibody were pre-incubated overnight prior to
the binding reaction.
Statistical analysis
Results are expressed as means  SD. The data are
presented as x-fold induction compared to control condi-
tions or compared to db-cAMP-stimulated values. Statis-
tical analysis was performed using the Student t test. P
values below 0.05 (control) and below 0.01 (control and
db-cAMP-stimulated) were considered significant.
RESULTS
Dexamethasone reduces the level of cAMP-induced
extracellular level of tPA activity and antigen
Our prior study demonstrated that IL-1 is a potent
inducer of tPA expression, whereas urokinase-type PA
(uPA) shows a low abundance in rat MC [9]. To test
whether the membrane-permeable cAMP analog dibu-
tyryl-cAMP (db-cAMP) could increase the level of se-
creted tPA activity and antigen, conditioned media from
MC were withdrawn after 24 hours of stimulation. Shorter
incubations with db-cAMP cells did not produce detect-
able amounts of tPA antigen (data not shown). As shown
in Figure 1A, treatment of MC with 2 mmol/L db-cAMP
caused an overall fivefold increase in the amount of tPA
enzyme activity as measured by ELISA. This increase
in activity was paralleled by an increased extracellular
tPA antigen level (Fig. 1B), thus demonstrating that the
rise in tPA activity mainly results from an increase in
tPA expression. To test for possible effects of dexameth-
asone on tPA activity and tPA antigen levels, MC were
incubated with db-cAMP (2 mmol/L) in the presence of
vehicle (control) or dexamethasone (100 nmol/L) or a
combination of dexamethasone plus the glucocorticoid
Fig. 1. Dexamethasone inhibits the cAMP-induced tissue plasminogenreceptor antagonist mifepristone (RU 486; 1 mol/L). activator (tPA) activity and tPA antigen in conditioned media from
Dexamethasone and RU 486 both were given in pre- mesangial cells (MC). (A) MC were treated with either vehicle (control),
db-cAMP (2 mmol/L), dexamethasone (Dex; 100 nmol/L) or the gluco-incubations of 30 minutes before addition of db-cAMP.
corticoid receptor (GR) antagonist mifepristone (RU 486; 1 mol/L)As shown in Figure 1B, treatment of MC with db-cAMP
for 24 hours before 100 L of cell culture supernatants were subjected
leads to a significant increase of basal level of tPA anti- to a Chromolize tPA ELISA (Biopool) to measure tPA activity as de-
scribed in the Methods section. (B) In parallel, 20 L from the samegen (2.3-fold compared to untreated controls) and was
cell culture supernatants were assessed for tPA antigen by the tPA Tintparalleled by an increase of extracellular tPA activity
Elize ELISA. Data represent means  SD (N  4). **P  0.01 com-(Fig. 1A). We observed that the net increase in tPA pared with vehicle, or db-cAMP-stimulated conditions (##P  0.01,
activity by db-cAMP in all experiments was higher than #P  0.05).
the rise in corresponding tPA protein. This indicates that
tPA enzyme activity, in addition to a regulation on the
expression level, is determined on a post-translational
was reversed upon co-incubation of MC with dexametha-level, most probably by a direct regulation of enzyme
sone and the GR antagonist RU 486. This demonstratedactivity by the endogenous inhibitors, the PAIs.
that the inhibitory effects on tPA expression by dexa-Both the db-cAMP–induced tPA antigen levels and
methasone were mediated by the GR.the db-cAMP–caused tPA activity were substantially re-
duced with dexamethasone by 84% and 46%, respectively.
Time course of modulation of cAMP-induced tPAThe compound on its own did not change the basal level
mRNA steady-state level by dexamethasoneof tPA protein nor did it affect basal tPA activity (Fig. 1).
To test further whether the dexamethasone-mediatedThe reduction in tPA antigen and to a lesser extent also
the inhibition of tPA enzyme activity by dexamethasone alterations of tPA activity and tPA antigen result from
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Fig. 2. Effects of different glucocorticoids on
cAMP-triggered tPA mRNA level in MC. (A)
Time-course of steady-state levels of tPA and
PAI-1 mRNA in MC following treatment with
vehicle (control) or db-cAMP (2 mmol/L) with
or without dexamethasone (Dex, 100 nmol/L)
in the presence or absence of RU 486 (1mol/L)
as indicated. Twenty micrograms of total cel-
lular RNA were hybridized successively to the
corresponding 32P-labeled cDNA inserts as de-
scribed in the Methods section. Equivalence
of loading was ascertained by rehybridization
to an 18S probe. The blot is representative
for three independent experiments. (B) Dose-
dependent inhibition of cAMP-induced tPA
steady-state mRNA levels by dexamethasone.
Quiescent MC were treated for the indicated
time points with vehicle (control), db-cAMP
(2 mmol/L) or db-cAMP in the presence of the
indicated concentrations of dexamethasone.
Twenty micrograms of total cellular RNA
were hybridized to a 32P-labeled cDNA insert
from KS-tPA. Equivalent loading of RNA was
ascertained by rehybridzation to a 18S rRNA
probe. The blot is representative for two in-
dependent experiments. (C ) Quiescent MC
were treated for 24 hours with vehicle (con-
trol), db-cAMP (2 mmol/L) or diverse syn-
thetic and natural glucocorticoids as indicated.
The concentrations of the GCs were as fol-
lowed: dexamethasone 100 nmol/L; predniso-
lone 100 nmol/L; fluocinolone 10 nmol/L; hy-
droxycortisone 1 mol/L. Twenty micrograms
of total RNA were hybridized successively to
a 32P-labeled cDNA insert from tKS-tPA and
a GAPDH probe. The blot is representative
of three independent experiments.
changes in mRNA level, Northern blotting was per- mRNA level at the later time point (24 hours). Dexa-
methasone alone had a weak stimulatory effect on theformed using a cDNA from the rat tPA gene. A represen-
tative time course experiment is shown in Figure 2A. basal level of tPA steady-state mRNA at the very early
time point tested (2 hours; Fig. 2A).Db-cAMP potently induced tPA expression in rat MC
at all time points tested, but the maximal stimulatory By testing dose-responsiveness of dexamethasone-
mediated modulation of tPA steady-state mRNA level,effects were seen between 5 and 24 hours of treatment.
Whereas dexamethasone at the early time points tested the inhibitory effects on tPA mRNA level occurred only
at the late time point (24 hours) but not at the earlyhad no inhibitory effects on the db-cAMP–induced steady-
state level of tPA mRNA, it strongly inhibited the tPA time point (5 hours) tested, independent of the concen-
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tration of dexamethasone used (Fig. 2B). For all further
experiments we therefore chose a concentration of 100
nmol/L of dexamethasone, which displayed a maximal
inhibitory effect on the tPA steady-state mRNA level.
Since the activity of tPA is physiologically inhibited by
specific serine proteinase inhibitors, we checked whether
dexamethasone additionally modulates the PAI-1 mRNA
level. PAI-1 gene expression in most cells is positively
regulated by glucocorticoids, due to the presence of a
glucocorticoid responsive element (GRE) in the PAI
gene promoter [25]. Interestingly, we observed that in
rat MC the basal steady-state level of PAI-1 mRNA was
suppressed by db-cAMP, but up-regulated by dexameth-
asone (Fig. 2A).
Next, the inhibitory effects of a range of different
glucocorticoids on db-cAMP-induced tPA mRNA levels
were compared. MC were treated for 24 hours with
db-cAMP in the presence of different synthetic or natu-
ral glucocorticoids. As shown in Figure 2C, all of these
glucocorticoids exerted a strong inhibitory effect on the
db-cAMP–mediated increase of tPA mRNA level (Fig.
2C), but had no effects on basal levels when given alone
(data not shown).
Activation of a 2.3 kb tPA promoter by cAMP is
inhibited by dexamethasone
To further evaluate whether the inhibitory effects of
dexamethasone on cAMP-mediated tPA expression oc-
cur on a transcriptional level, reporter gene assays were
performed. A 2.3 kb fragment from the 5-regulatory re-
gion of the rat tPA gene was isolated from genomic DNA
from rats by PCR using gene-specific primers. Transient
transfection of rat MC with the tPA-pGL-Luciferase re-
porter gene comprising 2.3 kb of the tPA promoter re-
gion and subsequent treatment with db-cAMP for 24
hours revealed a twofold increase in Luciferase activity
(Fig. 3A). Simultaneous treatment with dexamethasone
(100 nmol/L) completely inhibited db-cAMP-driven Lu-
ciferase activity but had no effects on the basal tPA pro-
moter activity (Fig. 3A). The high basal promoter activity
Fig. 3. (A) Dexamethasone inhibits the cAMP-stimulated tPA pro- observed in the Luciferase assays in our study may ex-
moter activity. Luciferase activities of a 2.3 kb pGLtPA-promoter hy- plain the only moderate increase in promoter activity
brid were determined. MC were transiently cotransfected in 6-well
caused by db-cAMP. Since the increase in mRNA levelplates using 0.4 g of pGL-tPA (2.3) and 0.1 g of pRL-CMV coding
for Renilla luciferase per well. After overnight transfection, MC were induced by db-cAMP showed a consistently higher mag-
treated for 24 hours with vehicle (control), db-cAMP (2 mmol/L), dexa- nitude than the increase in promoter activity, we cannot
methasone (Dex; 100 nmol/L) or a combination of db-cAMP and dexa-
exclude the involvement of more upstream modulatorymethasone before being harvested for measuring dual luciferase activi-
ties, as described in the text. The values for beetle luciferase were related elements that may impact on basal promoter activity as
to values for Renilla luciferase and are depicted as relative luciferase well as on the response to cAMP. Furthermore, dexa-activities. Data represent means  SD (N  4). *P  0.05, **P  0.01
compared with vehicle, or db-cAMP-stimulated conditions (##P 0.01).
(B) Activation of tPA promoter by cAMP depends on a CRE at 185
to 178 but not on an AP-1 at 984 to 978. Promoter activation by
db-cAMP of wild-type (pGL-tPA wt) and point-mutated (pGL-tPA-
	CRE; pGL-tPA-	AP-1) tPA promoter constructs was tested by mea- vested for measuring dual luciferase activities. The values for beetle
suring relative luciferase activity. After overnight cotransfection with luciferase were related to values for Renilla luciferase and are depicted
the indicated pGL-tPA constructs and pRL-CMV, MC were treated as relative luciferase activities. The data represent one of two indepen-
for 24 hours with or without db-cAMP (2 mmol/L) before being har- dent experiments performed in triplicate.
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methasone did not modulate the stability of db-cAMP– body. The addition of anti-CREB antibody caused a
supershift (arrow) and impaired DNA-binding (Fig. 4B).induced tPA mRNA (data not shown). This suggests
that the modulation of db-cAMP–induced tPA mRNA CRE-like sequences are not exclusively bound by
CREB, but in some gene promoters also are recognizedlevel in MC by dexamethasone was due mainly to an
inhibition of gene expression. by members of the CCAAT/enhancer-binding proteins
(C/EBPs) [26]. In rat MC, CREB in association with the
A CRE site within the rat tPA gene is critical for the inducible C/EBP  and 
-isoforms participates in the
cAMP response in MC transcriptional activation of inducible nitric oxide syn-
thase (iNOS) by cAMP [24]. Therefore, we tested forTo further delineate the promoter binding elements
critical for the inducibility of tPA expression by cAMP, presence of different C/EBPs in the cAMP-induced com-
plex. We focused on C/EBP and C/EBP
 because thesewe tested two different pGL-tPA-promoter constructs
bearing two single point mutations in the binding sites isoforms are involved in the transcriptional induction
of acute phase proteins and cytokines [27]. Supershiftof either CRE at 185 to 178 to create pGL-tPA-
	CRE, or alternatively two base mutations in a region analysis indicated the involvement of C/EBP, since ad-
dition of anti-C/EBP impaired the DNA binding. Inencompassing an AP-1 binding site at 984 to 978 to
create pGL-	AP-1, respectively (Table 1). AP-1 and contrast, incubation with an antibody against C/EBP

had no effect on DNA-binding (Fig. 4B). Furthermore,CRE are both common targets for the cAMP response
and additionally can be affected by glucocorticoids competition assays were performed using a 100-fold mo-
lar excess of unlabeled oligo encompassing either (a) a[20, 21]. Disruption of the CRE site completely pre-
vented tPA promoter activation by db-cAMP whereas tPA-specific CRE identical to that used as a probe in the
binding reaction or, alternatively, a CRE consensus oli-mutation of the AP-1 site did not affect promoter activa-
tion by db-cAMP (Fig. 3B), thus demonstrating that the gonucleotide bearing (b) a wild-type CRE or (c) a mu-
tated CRE. DNA-binding of the db-cAMP-inducibleCRE site at 185 to 178 is critical for the cAMP-
responsiveness of tPA expression in rat MC. complex was fully completed by addition of an excess
of unlabeled tPA-specific CRE (Fig. 4C). Similarly, the
Dexamethasone inhibits the DNA-binding of nuclear addition of a consensus wild-type CRE strongly impaired
factors interacting with the CRE DNA-binding. In contrast, the mutated CRE oligonucle-
otide was almost ineffective in competition, thus demon-To determine whether dexamethasone affects the
DNA-binding activity to CRE, EMSA was performed strating specificity of the DNA-bound complex.
Together these results indicate that CREB, in combi-using a radioactively labeled oligonucleotide encom-
passing the CRE site in the tPA promoter (Table 1). nation with C/EBP participates in the transcriptional
activation of the tPA gene by cAMP, most likely throughNuclear extracts were prepared from unstimulated MC
and from cells treated with db-cAMP alone or in combi- binding to a common promoter site.
nation with 100 nmol/L dexamethasone. A co-incubation
Inhibition of DNA-binding by dexamethasonefor five hours was chosen, since the maximal inhibitory
correlates with reduced level of transcriptioneffects on the steady-state mRNA level caused by dexa-
factors in cell nucleimethasone occurred between 5 and 24 hours of stimula-
tion (Fig. 2A). Nuclear extracts from untreated MC ex- The question of whether the dexamethasone-mediated
changes in CRE DNA-binding were attributable to anhibited a moderate constitutive binding to CRE, which
was strongly induced upon treatment of cells with inhibition of nuclear translocation of the correspond-
ing transcription factors was elucidated. To this end, nu-db-cAMP (Fig. 4A). The DNA-binding of this complex
was strongly reduced by dexamethasone (Fig. 4A). Fur- clear extracts were successively probed with antibodies
specific for the glucocorticoid receptor (GR), CREB,thermore, addition of the GR antagonist mifepristone
(RU 486) restored the full CRE-binding capacity, thus phosphorylated CREB (phospho-CREB), and C/EBP,
respectively.demonstrating involvement of a GR-dependent mecha-
nism (data not shown). As shown in Figure 5, treatment of MC with db-cAMP
triggered a significant increase in the nuclear levels ofTo test for specificity of CRE-binding we additionally
used a mutated probe comprising an exchange of two phosphorylated CREB and C/EBP that was inhibited
in the presence of dexamethasone. Interestingly, CREBbase pairs within the CRE motif (Table 1). Replacement
of the CRE wild-type oligo with this mutant CRE probe showed a constitutive nuclear abundance that was not
significantly modulated by db-cAMP or dexamethasone,in the binding reaction results in an almost total inhibi-
tion of DNA-binding capacity, thus demonstrating speci- indicating that the changes in CRE-binding were mainly
due to changes in the phosphorylation status of CREBficity of DNA binding (data not shown). The presence
of CREB in the DNA bound complex was proved by (Fig. 5). Furthermore, the appearance of a GR-positive
band upon dexamethasone treatment emphasizes thesupershift analysis using a polyclonal CREB-specific anti-
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Fig. 4. Dexamethasone inhibits db-cAMP–induced DNA-binding to a tPA-specific CRE. The sequences of the oligonucleotides used as probes
and for competition are depicted in Table 1. (A) The db-cAMP–induced binding to a gene-specific CRE motif is suppressed by dexamethasone
(Dex). Nuclear extracts were prepared from quiescent MC treated for 5 hours with (control), db-cAMP (2 mmol/L), dexamethasone (100 nmol/L)
or a combination of db-cAMP and dexamethasone. The cAMP-induced DNA binding to a region encompassing 195 to 166 of the rat tPA
promoter is inhibited when cells were simultaneously treated with dexamethasone. (B) Characterization of db-cAMP-induced complex binding to
tPA-specific CRE by supershift analysis. For the supershift analysis, the indicated antibodies were pre-incubated overnight before the addition of
the labeled probe. (C ) Characterization of db-cAMP–induced complex binding to tPA-specific CRE by competition analysis. Competitions were
performed using a 100-fold molar excess of either unlabeled wild-type CRE (CRE-tPA), a consensus wild-type CRE (CRE-cons.wt), or a consensus
CRE oligo bearing a mutation within the consensus motif (CRE-cons.mut). The sequences used for mutation of the tPA-CRE are depicted in
Table 1. For competition the corresponding double-stranded unlabeled oligonucleotide was added to the binding reaction. The EMSA shown is
representative of three independent experiments giving similar results.
fact that the nuclear import of GR depended on the 39 kD, corresponding to the size of C/EBP, was strongly
presence of the GR agonist dexamethasone. The addi- increased by db-cAMP and reached the maximal level
tion of RU 486 resulted in a significant reduction of after 24 hours of stimulation (Fig. 6), which corre-
the nuclear GR level, indicating that RU 486 interfered sponded to the time course of induction of C/EBP
with nuclear translocation of GR. Moreover, RU 486 mRNA by cAMP [24]. Most interestingly, while having
prevented the dexamethasone-mediated suppression of no effect by itself, dexamethasone further augmented
the db-cAMP-triggered increase in phospho-CREB and the db-cAMP–triggered C/EBP protein level, particu-
C/EBP levels, thus indicating a GR-mediated mecha- larly at the late 24-hour time point (Fig. 6). In contrast,
nism. In summary, these data demonstrate that the dexa- the level of CREB remained unchanged under all condi-
methasone-mediated inhibition in DNA-binding of CREB tions tested, thus indicating that the activity of CREB
and C/EBP is paralleled by a reduction in the nuclear in rat MC was primarily regulated by phosphorylation.
levels of C/EBP and phosphorylated CREB without
affecting the nuclear level of total CREB.
DISCUSSION
Effects of cAMP and dexamethasone on cellular The present study investigated the mechanisms of
levels of CREB and C/EBP dexamethasone modulation of cAMP-triggered tPA ex-
pression in rat glomerular MC. Dexamethasone signifi-To evaluate whether the changes in nuclear phospho-
cantly reduces the db-cAMP–stimulated increase in tPACREB- and C/EBP reflect changes in the total cellular
activity in MC culture supernatants mainly by an inhibi-levels of CREB or C/EBP, both transcription factors
tion of tPA expression. Activation of the plasminogen/were monitored by Western blot analysis using cell ho-
plasmin system by cAMP in MC operates at two differentmogenates (Fig. 6). Several reports have shown that glu-
levels; one involves a direct activation of tPA expressioncocorticoids and cAMP are potent inducers of C/EBP
expression [24, 28, 29]. An immunopositive signal at whereas the other operates by a reduction of PAI-1, the
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Fig. 5. Dexamethasone inhibits the cAMP-induced phosphorylation of CREB and C/EBP. For Western blot analysis, 30 g of the same nuclear
extracts used for EMSA shown in Figure 4 were successively probed with the indicated antibodies. The migration properties of each transcription
factor were determined by use of molecular weight markers. Equal protein loading was ascertained by Ponceau-S staining. (B) Densitometric
analysis of the Western blot (A). Blots are representative of three independent experiments giving similar results.
endogenous inhibitor of tPA. In other cells, it has been triggered tPA activity mainly results from inhibition of
tPA expression.reported that an increase in PAI-1 synthesis is the main
mechanism of glucocorticoid suppression of tPA activity Although the modulation of tPA expression by gluco-
corticoids has been amply documented the final outcome[30]. However, in MC the inhibition on the db-cAMP–
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Fig. 6. Dexamethasone does not alter total
cellular CREB and C/EBP levels. Total cel-
lular content of CREB and C/EBP protein
in quiescent MC treated for the indicated time
periods with vehicle (control), db-cAMP (2
mmol/L) in the presence or absence of dexa-
methasone (Dex; 100 nmol/L) as indicated.
Protein lysates (100 g) were subjected to
SDS-PAGE and immunoblotted successively
using the antibodies recognizing CREB-1 or
C/EBP, respectively, as indicated. Equal pro-
tein loading was ascertained by Ponceau-S
staining. The experiment is representative of
three independent experiments.
is quite diverse, ranging from a pure inhibition [31] to a transcriptional activation of tPA by cAMP elevating
agents in the rat glioma cell line C6 [14]. Interestingly,strong amplification of tPA expression [15, 32]. Obvi-
ously, cell-type specific regulation that may rely on the in primary cultures of rat hepatocytes dexamethasone
exerts biphasic effects on the basal tPA mRNA expres-concerted action of different patterns of transcriptional
activators governs tPA expression by glucocorticoids. sion depending on the concentration used. Whereas
higher concentrations of dexamethasone (108 to 106Physiologically, dexamethasone significantly can affect
the fibrinolytic activity within different organs including mol/L) potently suppressed the tPA expression, a lower
concentration (1010 mol/L) significantly elevated tPAheart, brain and liver [33]. Similarly to MC, hydroxycorti-
sone also inhibits the db-cAMP–mediated induction of expression [36]. Similarly, the dose-dependent effects by
dexamethasone were reflected on the level of tPA activ-tPA mRNA in murine keratinocytes, which may consti-
tute one facet of the well known alterations of wound ity. By contrast, in rat MC all concentrations of dexa-
methasone uniformly exert inhibitory effects (Fig. 2B).healing by glucocorticoids [34]. With regard to this com-
plex process, which is characterized by temporally and The late reduction of cAMP-triggered tPA mRNA also
is reflected by a reduction in tPA activity, thus indicatingspatially overlapping phases of tissue remodeling, it be-
comes obvious that wound healing prototypically resem- that dexamethasone exerts an overall inhibitory effect
on tPA resulting from combined alterations of tPA andbles processes that generally occur also in the kidney
[35]. The synergistic induction of tPA transcription by PAI-1 expression. Whereas most of the positive tran-
scriptional effects exerted by glucocorticoids have beencAMP and dexamethasone in rat hepatoma cells, simi-
larly to the inhibition of tPA expression observed in the attributed to GREs, the negative actions in most cases
arise from interactions with and scavenging of diversepresent study in MC, mainly depends on transcriptional
events. Moreover, the synergistic increase in tPA mRNA transcriptional activators by the GR, thereby leading to
an inhibition of gene transcription.level observed in these cells could not be attributed to
the proximal 2.3 kb portion of the 5 flanking region of In MC, glucocorticoids most efficiently inhibit the ex-
pression of a variety of genes that similarly can be trig-the tPA gene, indicating that a positive regulation by
dexamethasone depends on promoter elements lying up- gered by the proinflammatory cytokines IL-1 and TNF,
but, remarkably, also by cAMP-elevating agents. Thesestream of this proximal region [15]. In contrast, in MC
the inhibition of cAMP-triggered tPA expression by include genes coding for secretory phospholipase A2
(sPLA2) [37–39], iNOS [40–42], and guanosine 5-tri-dexamethasone is fully constituted within the proximal
2.3 kb of the tPA promoter. Furthermore, our study phosphate (GTP) cyclohydrolase I [43]. Interestingly,
the mechanisms of glucocorticoid-mediated inhibition ofdemonstrated that the transcriptional regulation of tPA
expression by cAMP in MC critically depends on a CRE cytokine-induced genes in MC are quite variable, com-
prising exclusively transcriptional actions [39] as wellsite at 177 to 185 and the mutation of this site results
in a complete loss of promoter activation by db-cAMP. as mechanisms that combine transcriptional and post-
transcriptional actions [42]. In contrast, the inhibition ofSince this mutation did not reduce the basal promoter
activity, we conclude that binding to CRE exclusively cAMP-triggered expression of iNOS, sPLA2 and GTP-
cyclohydrolase I by dexamethasone predominantly oc-depends on stimulations with cAMP. This is in a full
agreement with recent studies demonstrating the func- curs on a transcriptional level. Performing experiments
with actinomycin-D, we found that dexamethasone in rattional importance of a corresponding CRE site for the
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MC did not significantly reduce stability of tPA mRNA. db-cAMP treatment was substantially reduced by dexa-
Therefore, we conclude that, similar to iNOS, sPLA2 and methasone in a manner that was dependent on GR. This
GTP-cyclohydrolase I, the inhibition of cAMP-triggered reduction in nuclear C/EBP level is not paralleled by
tPA expression results mainly from a transcriptional reg- a decrease in the total amount of cellular C/EBP. By
ulation by dexamethasone (W.E., unpublished observa- contrast, long-term treatment with db-cAMP and dexa-
tions). The transcriptional modulation of cAMP-induced methasone further augments the cAMP-evoked increase
tPA gene expression by glucocorticoids can be attributed in total C/EBP levels, whereas dexamethasone alone
to a CRE within the tPA gene promoter as documented had no effects.
by EMSA and reporter gene assay. A suppressive effect In summary, the present study emphasizes the func-
on cAMP-triggered gene transcription by glucocorticoids tional role of CREB and C/EBP transcription factors
through interference with a CRE also has been described as glucocorticoid-sensitive regulators of tPA expression.
for -gonadotropin gene expression [21]. The underlying Therapies aiming at enhancing or replacing fibrinolytic
mechanism involves a steric inhibition of CREB binding activity in crescent glomerulonephritis are considered
through overlapping GRE and CRE binding sites. How- beneficial in human disease [7]. In this context, our study
ever, since the CRE region within the rat tPA promoter may help to understand the molecular basis for patho-
contains no flanking GRE-like sequences, such a mecha- logic processes within the glomerulus seen after long-
nism does not account for the observed inhibition in rat term treatment with glucocorticoids.
MC. We demonstrate that in rat MC the inhibition of
CRE binding is due to an inhibition of CREB phosphory- ACKNOWLEDGMENTS
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Abbreviations used in this article are: cAMP, cyclic adenosine 35-in the pituitary gland of mice [45]. Furthermore, there
monophosphate; C/EBP, CCAAT/enhancer binding protein; CREB,
is a clear functional correlation between the phosphory- cAMP response element binding protein; db-cAMP, dibutyrylguano-
lation status of CREB and its DNA-binding capacity sine-cyclic adenosine 3,5-monophosphate; ECM, extracellular matrix;
ELISA, enzyme-linked immunosorbent assay; EMSA, electrophoretic[46, 47].
mobility shift assay; FSH, follicle stimulating factor; GR, glucocorticoidIn addition and similarly to CREB, we have demon- receptor; GRE, glucocorticoid response element; GTP, guanosine 5-
strated that C/EBP can bind to the CRE site of the triphosphate; IL-1, interleukin-1; iNOS, inducible nitric oxide syn-
thase; MC, mesangial cells; MMP, matrix metalloproteinase; NF-B,tPA gene promoter upon cAMP stimulation. Several
nuclear factor-B; PAI, plasminogen activator inhibitor; PAs, plasmin-observations indicate a functional redundancy between
ogen activators; PMA, phorbol 12-myristate 13-acetate; TNF-, tumor
CREB and members of the C/EBP transcription factor necrosis factor-; tPA, tissue plasminogen activator; uPA, urokinase-
type plasminogen activator.family by binding to a common CRE motif [48]. Su-
pershift analysis indicates that C/EBP rather than
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